NCT06684873View on ClinicalTrials.gov

A Multicenter, Single-arm, Open-label Study Evaluating the Safety and Efficacy of AK112 Combined With Chemotherapy as First-line Treatment for Non-squamous NSCLC Patients With BRAIN Metastases and Negative Driver Genes (IVO BRAIN)

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 2, 2024

Primary Completion Date

December 1, 2027

Study Completion Date

December 1, 2027

Conditions

NSCLCBrain Metastasases

Interventions

DRUG

AK112 Injection

AK112 injection plus chemotherapy was administered to all eligible patients

Trial Locations (1)

510000

Sun Yat-Sen University Cancer Center, Guangzhou

All Listed Sponsors

lead

Sun Yat-sen University

OTHER

NCT06684873 - A Multicenter, Single-arm, Open-label Study Evaluating the Safety and Efficacy of AK112 Combined With Chemotherapy as First-line Treatment for Non-squamous NSCLC Patients With BRAIN Metastases and Negative Driver Genes (IVO BRAIN) | Biotech Hunter | Biotech Hunter